| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -143,862 | -96,210 |
| Depreciation and amortization | 1,683 | 1,218 |
| Stock-based compensation expense | 7,550 | 5,201 |
| Net accretion of discount on marketable securities | 544 | 528 |
| Non-cash lease expense | 165 | 82 |
| Non-cash sublease loss | 982 | 982 |
| Loss on disposal of property and equipment | -8 | - |
| Other | -13 | -12 |
| Prepaid expenses and other current assets | -2,703 | -1,568 |
| Deposit and other long-term assets | 676 | 125 |
| Accounts payable | 10,842 | 3,103 |
| Accrued expenses and other liabilities | 10,815 | 3,625 |
| Lease liability | 668 | -466 |
| Net cash used in operating activities | -109,653 | -81,538 |
| Purchases of marketable securities | 1,976 | 1,976 |
| Maturities of marketable securities | 67,500 | 65,500 |
| Purchases of property and equipment | 482 | 340 |
| Net cash provided by (used in) investing activities | 65,042 | 63,184 |
| Proceeds from issuance of common stock and pre-funded warrants in private placements, net of issuance costs | 9,899 | 0 |
| Proceeds from issuance of common stock pursuant to option exercises | 0 | 0 |
| Proceeds from employee stock purchase plan | 120 | 120 |
| Net cash provided by financing activities | 10,019 | 120 |
| Net (decrease) increase in cash and cash equivalents and restricted cash | -34,592 | -18,234 |
| Cash and cash equivalents at beginning of period | 62,628 | - |
| Cash and cash equivalents at end of period | 28,036 | - |
Adverum Biotechnologies, Inc. (ADVM)
Adverum Biotechnologies, Inc. (ADVM)